Tirzepatide (mounjaro) 5mg 10mg 15mg naliti

Tirzepatide (mounjaro) 5mg 10mg 15mg inaliti Umfanekiso ofakiweyo

inkcazelo emfutshane:

Igama: Tirzepatide

Iimpawu: 5mg / ibhotile * 10 iivials / ibhokisi 10mg / ibhotile * 10 ibhodlela / ibhokisi 15mg / ibhotile * 10vial / ibhokisi

Ixabiso: 5mg USD110 / ibhokisi 10mg USD220 / ibhokisi 15mg USD330 / ibhokisi

Lab: Lianfu Bio

MOQ: 1 ibhokisi

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Tirzepatide

I-Tirzepatide luphando oluphandwayo kanye ngeveki, i-insulinotropic polypeptide exhomekeke kwi-glucose kabini kunye ne-glucagon-like peptide-1 receptor agonist edibanisa izenzo zombini i-incretins kwi-molecule enye.

I-Tirzepatide Mimics IiHormone zeNdalo ezikhuthaza ukuziva ngokupheleleyo
I-Tirzepatide isebenza ngokulinganisa iihomoni ze-GLP-1 kunye ne-GIP ezikhutshelwa ngokwemvelo ngamathumbu emva kokutya, nto leyo ebangela ukukhutshwa kwe-insulin.Ikwanciphisa umdla wokutya ngokucutha ixesha elithatha isisu ukuba singabi nanto kwaye sinxibelelane neendawo ezisebuchotsheni ezigcina ii-receptors ze-GLP-1 ukubonisa ukuhlutha.

I-Tirzepatide liyeza elinoveli elivunywe yi-FDA kunyango lwe-2 yesifo seswekile.Ngenxa yeempawu zayo ezinamandla zokunciphisa umzimba,tirzepatidezisetyenziswe ngaphandle kweleyibhile kunyango lokutyeba.Isebenza njenge-agonist ye-GLP-1 kunye ne-GIP ye-agonist yokwandisa izibonelelo ezifanayo ezibonwa ngamayeza e-GLP-1 afana ne-semaglutide.Kungoku nje iphunyezwa njengeyeza lesibini lesifo seswekile, elifana namayeza e-GLP-1, kwaye linikezelwa njengetofu engaphantsi kwesikhumba kanye ngeveki.

I-Tirzepatide yi-glucose exhomekeke kwi-insulinotropic polypeptide (GIP) receptor kunye ne-glucagon-like peptide-1 (GLP-1) i-recepto agonist, evunywe yi-FDA ukunyanga uhlobo lwe-2 yesifo sikashukela.Kubalulekile ukuba uqaphele ukuba i-tirzepatide ayivunywanga ukunyanga i-1 yesifo sikashukela kwaye ayizange ifundwe kwizigulane ezine-pancreatitis.I-Tirzepatide i-GIP receptor kunye ne-GLP-1 i-receptor agonist, ekhokelela ekuphuculeni kakhulu ukulawulwa kwe-glycemic kuhlobo lwe-2 yesifo sikashukela kunye nokunciphisa ubunzima obunzima.

I-FDA ivume i-Tirzepatide ngoMeyi 2022. I-Tirzepatide ingasetyenziselwa ngaphandle kweleyibhile ukunyanga ukutyeba.Okwangoku iphunyezwa njengeyeza lesibini lesifo seswekile, elifana namayeza e-GLP-1 afana ne-semaglutide.Liyeza elitofwayo elitofwa kanye ngeveki elinokonyuka kwethamo.

Idatha yangoku yeklinikhi ibonise ukuba i-tirzepatide iphezulu kune-placebo ekuphuculeni amanqanaba e-hemoglobin A1C.Ulingo lwekliniki lwe-SURPASS-5 lubonise ukunciphisa -2.11% kumanqanaba e-hemoglobin A1C kwi-5mg ngeveki dosing, xa kuthelekiswa ne-0.86% kunye ne-placebo.Kwinqanaba eliphezulu le-15 mg ngeveki, i-tirzepatide iholele ekunciphiseni kwe-2.34% kwi-hemoglobin A1C.Oku kuboniswe kwiiveki ezingama-40.Ukunciphisa ubunzima be-5.4 kg kubonwe nge-5mg ye-tirzepatide dosing, kwaye ukunciphisa i-10.5 kg kubonwe nge-15 mg dosing.Olu lungelelwaniso oluxhomekeke kwidosi kunye nokulahleka kwesisindo lufana ne-semaglutide, iyeza eliqhelekileyo le-GLP-1 elisetyenziselwa ukulawula ukulahleka kwesisindo.

Ngokuthelekisa, i-tirzepatide ibonakaliswe isebenza ngokufanayo kumayeza e-GLP-1 kodwa ngokusebenza ngakumbi.Ukunikezelwa kweempawu zayo zokulahlekelwa kwesisindo kunye nokungabikho kwetyhefu yesibindi, kunokwenzeka ukuba idlale indima engathanga ngqo kunyango lwe-noncoholic fatty liver disease (NAFLD) ngokunjalo.